Only 3 Days Left to Secure Early Bird Access to BiOPartnering at BIOCHINA 2026

Suzhou, China – With just three days remaining until early bird registration closes, BIOCHINA 2026 is set to welcome top global players in the pharmaceutical industry to its highly anticipated BiOPartnering platform. Leading multinational companies including Bayer, Eli Lilly, Pfizer, Novartis, BMS, Hikma, and Dr. Reddy’s are forming dedicated teams to actively source innovative projects from China, highlighting the growing importance of cross-border collaboration in biotech and pharma.

BiOPartnering at BIOCHINA 2026 offers participants an unparalleled opportunity to connect directly with high-level executives and decision-makers. Attendees can schedule pre-matched 1V1 meetings focused on biologics, novel therapeutics, and enabling technologies. These goal-oriented sessions are designed to accelerate licensing deals, strategic partnerships, and investment opportunities, providing a fast-track route for innovation to reach global markets.

For innovators, startups, and established companies alike, BiOPartnering provides a platform to showcase projects, explore collaborative opportunities, and engage with executives responsible for R&D sourcing and business development. The event is especially valuable for organizations seeking to expand internationally or gain insight into emerging trends in the Chinese biotech ecosystem.

Early Bird Advantage:

Secure your spot now to lock priority meeting slots and save $150 on registration. Early registration ensures you connect with the right partners before slots fill.

Register now: https://u.morebio.cn/MnEjmeQF

Learn more: https://www.biocn.cn/en/en.html

BiOPartnering at BIOCHINA2026 is where real deals, licensing agreements, and strategic partnerships happen—don’t miss your chance to be part of it.